HAYWARD, Calif., Nov. 9, 2016 /PRNewswire/ -- Impax Laboratories, Inc. (NASDAQ: IPXL), a specialty pharmaceutical company, today reported third quarter 2016 financial results for the quarter ended September 30, 2016.
Total revenues in the third quarter 2016 increased 3% to $227.9 million, compared to $221.1 million in the prior year period.
The increase was due to a 30% increase in Specialty Pharma division revenues primarily as a result of higher sales of Rytary® and Zomig® nasal spray.
